We could not find any results for:
Make sure your spelling is correct or try broadening your search.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...
Assets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical...
Transaction consideration provides a significant premium to the Appili shareholders Combined enterprise expected to provide enhanced synergies and resources to advance key programs NOT FOR...
HALIFAX, Nova Scotia, March 12, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development...
FDA approved LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL Additional USAFA funding commitment from the U.S. Air Force Academy, intended to advance the ATI-1701 program toward an...
Patent coverage provides drug market exclusivity through at least 2039 Pre-IND meeting with the FDA granted to discuss ATI-1701’s regulatory, CMC, toxicology, and Phase 1 strategies Appili...
FDA approves ATI-1501 for Metronidazole Oral Suspension 500mg/5mL and its brand name LIKMEZ™ Appili received an additional funding commitment from the U.S. Air Force Academy for ATI-1701...
Additional US$6.6 million funding commitment for ATI-1701 brings the total program funding awarded to approximately US$14 million These funds along with other potential funding sources, are...
The morning opened up on a high note for this dually-listed company as it announced U.S. Food and Drug Administration (FDA) approval of its Metronidazole Oral Suspension 500mg/5mL ( ATI-1501 ) To...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.005 | -12.5 | 0.04 | 0.04 | 0.03 | 231420 | 0.035 | CS |
4 | -0.005 | -12.5 | 0.04 | 0.045 | 0.03 | 247285 | 0.03553042 | CS |
12 | 0.005 | 16.6666666667 | 0.03 | 0.06 | 0.025 | 240842 | 0.04062885 | CS |
26 | 0 | 0 | 0.035 | 0.06 | 0.025 | 164003 | 0.03816279 | CS |
52 | -0.005 | -12.5 | 0.04 | 0.08 | 0.025 | 203437 | 0.04707684 | CS |
156 | -1.215 | -97.2 | 1.25 | 1.25 | 0.025 | 193448 | 0.15082012 | CS |
260 | -1.095 | -96.9026548673 | 1.13 | 1.6 | 0.025 | 182385 | 0.29347682 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions